Dendrite Enables Sales Force Automation and Sample Management for DFB Pharmaceuticals' Traditional and Institutional Sales Force

Dendrite International, Inc. (NASDAQ: DRTE), a leading provider ofpharmaceutical industry solutions, today announced that DFBPharmaceuticals Inc., a privately held, rapidly growing pharmaceuticalcompany, will automate its domestic primary care and institutionalsales forces using Dendrite's latest sales force effectivenesssolution.

The relationship between the companies was first established inthe fourth quarter of 2005, when DFB contracted Dendrite for salesforce automation and sample management solutions. Under terms of thecontract, Dendrite will provide DFB with its Mobile Intelligence(TM)sales force automation solution. Mobile Intelligence will enable DFBto support its traditional and institutional sales forces through aninnovative and user-centric navigation tool that has been reengineeredto mirror the workflow of the sales representative. Built onMicrosoft's(R) .NET platform, Mobile Intelligence will enable DFB tointegrate Dendrite's solution easily into current and futuretechnology plans.

"Dendrite came out on top in our evaluation of companies thatcould meet our immediate and long term needs for both effectivecustomer relationship and sample management," said Michael Patterson,chief financial officer at DFB Pharmaceuticals.

"We believe DFB's confidence in selecting Dendrite to automate itssales force for the first time speaks volumes about the value we bringto pharmaceutical companies of all sizes," said Joseph Ripp, presidentand chief operating officer at Dendrite. "Supporting DFB with acomprehensive sample management solution is additional evidence thatDendrite is not only a sales force effectiveness company, but also abroad solutions provider that is able to address multiple pressurepoints for our customers."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the global,pharmaceutical industry. The Company's clients are located in morethan 50 countries and include the world's top 20 pharmaceuticalcompanies. For more information, please visit www.dendrite.com.

About DFB Pharmaceuticals

DFB Pharmaceuticals Inc. is a privately held corporation thatprovides technology-driven pharmaceutical products, outsourcingservices, and licensing opportunities to the healthcare industryworldwide through its branded marketing affiliate organizations andcontract partners. Headquarters are in Fort Worth, Texas. Affiliatesinclude DPT Laboratories Ltd., and HEALTHPOINT Ltd. Visit www.dfb.comfor additional information.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; fluctuations in quarterly revenues due tolengthy sales and implementation cycles for certain of our solutions;our fixed expenses in relation to fluctuating revenues and variationsin customers' budget cycles; dependence on certain major customers;changes in demand for our products and services attributable to anyweakness experienced in the economy or mergers, acquisitions andconsolidations in the pharmaceutical industry; successful and timelydevelopment and introduction of new products and versions; rapidtechnological changes; increased competition; internationaloperations; integrating the entities we acquire; our ability toeffectively manage our growth; the protection of our proprietarytechnology; our ability to compete in the Internet-related productsand services market; the continued demand for Internet-relatedproducts and services; the ability of our third party vendors torespond to technological change; our ability to maintain ourrelationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.